A role for the thromboxane receptor in L-NAME hypertension

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 4, 2008, Pages

  Francois, Helene ^a   Makhanova, Natalia ^a   Ruiz, Philip ^c   Ellison, Jonathan ^a   Mao, Lan ^b   Rockman, Howard A ^b   Coffman, Thomas M ^a,d  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac hypertrophy; Cardiovascular disease; Prostanoids; Renal injury

Indexed keywords

DRINKING WATER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; SODIUM CHLORIDE; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; GLOMERULOSCLEROSIS; HEART VENTRICLE HYPERTROPHY; HIGH SODIUM INTAKE; HYPERTENSION; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY INTERSTITIUM; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; STRAIN DIFFERENCE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE LEVEL; WILD TYPE;

EID: 57049184717     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00369.2007     Document Type: Article

References (43)

1. Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taniyama Y, Abe K. Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 96: 657-664, 1995.
2. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101: 2833-2840, 2000.
3. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
4. 2-prostaglandin H2 and renovascular hypertension in rats. Am J Physiol Regul Integr Comp Physiol 267: R1190-R1197, 1994.
5. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63: 579-605, 2001.
6. Bustos M, Coffman TM, Saadi S, Platt JL. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 100: 1150-1158, 1997.
7. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 101: 2780-2789, 1998.
8. 2. Science 296: 539-541, 2002.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003.
10. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994.
11. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH, Coffman TM. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2: 201-207, 2005.
12. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin II-induced hypertension. Hypertension 43: 364-369, 2004.
13. Fujihara CK, Michellazzo SM, de Nucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol Renal Fluid Electrolyte Physiol 266: F697-F705, 1994.
14. Garg UC, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol Renal Fluid Electrolyte Physiol 257: F60-F66, 1989.
15. Grieve EM, Hawksworth GM, Simpson JG, Whiting PH. The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition. Biochem Pharmacol 45: 1351-1354, 1993.
16. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15, 2006.
17. Hantz H, Adesuyi A, Adebayo O. Differential effects of U46619 on renal regional hemodynamics in the rat: involvement of endothelin. J Pharmacol Exp Ther 299: 372-376, 2001.
18. Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 70: 101-113, 2004.
19. Himmelstein SI, Klotman PE. The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats. Am J Physiol Renal Fluid Electrolyte Physiol 257: F190-F196, 1989.
20. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995.
21. 2 mediates cisplatin-induced apoptosis of renal tubule cells. Biochem Mol Biol Int 42: 113-121, 1997.
22. Kawada N, Dennehy K, Solis G, Modlinger P, Hamel R, Kawada JT, Aslam S, Moriyama T, Imai E, Welch WJ, Wilcox CS. TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am J Physiol Renal Physiol 287: F753-F759, 2004.
23. Keen HL, Brands MW, Smith MJ Jr, Shek EW, Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension 29: 310-314, 1997.
24. Kim YJ, Park YH, Moon HK. Reduction of chronic ciclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046. Kidney Blood Press Res 20: 38-43, 1997.
25. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995.
26. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D, Sterzel RB. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 14: 396-403, 1989.
27. Matsuo Y, Takagawa I, Koshida H, Kawabata T, Nakamura M, Ida T, Zhou L, Marumo F. Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 50: 1-8, 1995.
28. 2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 85: 4511-4515, 1988.
29. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, Awad JA, Roberts LJ. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 31: 117-139, 1999.
30. Nasjletti A, Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. Hypertension 31: 194-200, 1998.
31. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666, 1993.
32. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris R, Fogo A, Breyer M. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596, 2004.
33. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303, 1992.
34. Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 47: 1168-1175, 1995.
35. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 71: 266-271, 2007.
36. Takahashi N, Takeuchi K, Abe T, Sugawara A, Abe K. Immunolocalization of rat thromboxane receptor in the kidney. Endocrinology 137: 5170-5173, 1996.
37. 2. J Clin Invest 102: 1994-2001, 1998.
38. Tolins JP, Shultz PJ. Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt. Kidney Int 46: 230-236, 1994.
39. 2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 178: 1825-1830, 1993.
40. Vaskonen T, Mervaala E, Krogerus L, Teravainen TL, Laakso J, Karppanen H, Vapaatalo H. Cardiovascular effects of chronic inhibition of nitric oxide synthesis and dietary salt in spontaneously hypertensive rats. Hypertens Res 20: 183-192, 1997.
41. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, Takahata O, Yamada T, Murata T, Narumiya S, Ushikubi F. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104: 2210-2215, 2001.
42. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 27: 1165-1172, 1996.
43. 2 synthetase inhibitor, DP-1904, in lupus nephritis. J Rheumatol 23: 1719-1724, 1996.